Repligen appoints Pax to board of directors

Repligen Corporation (RGEN) announced the appointment to its Board of Directors of life sciences industry executive Maggie Pax. This appointment expands the size of Repligen’s board from eight to nine members. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific (TMO), where, from 2016-2020, she served as Vice President, Strategy and Innovation for the clinical supply chain business